エントロコッカス・フェシウム129 BIO 3B- Rが,ヘリコバクター・パイロリ根絶療法による成人患者への副作用への影響:ランダム化,ダブルブラインド,プラセボ対照試験
Eri Tokunaga1,2, Jun Inoue3, Naoki Asaji1
1Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Scientific reports
|September 1, 2025
まとめ
この研究では,プロバイオティクスのEnterococcus faecium 129 BIO 3B- Rがヘリコバクター・パイロリの根絶中に下痢に影響を及ぼすかどうかを調べました. プロバイオティクスを使用した高齢患者 (70歳以上) は,治療後の下痢が少なく,腸内微生物群の多様性が維持された.
科学分野:
- 微生物学
- 胃腸内科
- 薬理学について
背景:
- 腹はヘリコバクター・パイロリ根絶治療の一般的な副作用で,しばしば腸内微生物不活性症に関連しています.
- これらの副作用の管理は,治療の順守と成功に不可欠です.
研究 の 目的:
- 成人におけるH. pyloriの根絶療法中の副作用に対するプロバイオティック菌株Enterococcus faecium 129 BIO 3B- Rの影響を評価する.
- このプロバイオティックの腸内微生物多様性への影響を評価する.
主な方法:
- 76人の成人を対象としたダブルブラインド ランダム化制御試験で H. pylori の根絶が行われました.
- 参加者はEnterococcus faecium 129 BIO 3B- Rまたはプラセボを投与された.
- 年齢分別分析が行われました.
主要な成果:
- 一般集団では,下痢の発生率や微生物群の多様性において有意な差異は見られなかった.
- 70歳以上の参加者において,Enterococcus faecium 129 BIO 3B- Rの使用は,根絶後の下痢の減少と関連していた (23. 1% vs 60%).
- このプロバイオティクスのグループでは 腸内微生物のアルファ多様性も高かった.
結論:
- エントロコッカス・フェシウム129 BIO 3B- Rは,H. pyloriの根絶を受けた70歳以上の高齢者の下痢および腸内不活性症の緩和に役立ちます.
- このプロバイオティクスは,この特定の集団における治療耐性を改善する可能性を示しています.
- 高齢者におけるこれらの発見を確認するために,さらなる研究が必要である.
関連する概念動画
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
546
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
546
01:26Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145
01:23Gastritis III: Clinical Manifestations and Management
466
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
466
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
525
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
525
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
523
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
523
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
200
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
200